Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 5/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22022940 | 1.00 | PTGS1 (0.33) | PTGS1PTGS2MGLLFAAHKMT2A | |
| SCHEMBL22958884 | 0.98 | PTGS1 (0.33) | PTGS1PTGS2MGLLFAAHKMT2A | |
| SCHEMBL22952732 | 0.74 | CNR1 (0.31) | — | |
| SCHEMBL25101264 | 0.73 | TLR8 (0.40) | KMT2AHTTSMN1; SMN2TLR8 | |
| SCHEMBL20047667 | 0.73 | TLR8 (0.40) | KMT2AHTTSMN1; SMN2TLR8 | |
| SCHEMBL22388573 | 0.73 | TLR8 (0.40) | KMT2AHTTSMN1; SMN2TLR8 | |
| SCHEMBL26849577 | 0.72 | CNR2 (0.35) | KMT2A | |
| SCHEMBL22955757 | 0.71 | ALDH1A1 (0.32) | — | |
| SCHEMBL26850320 | 0.71 | TBXAS1 (0.33) | PTGS1PTGS2MGLLFAAHKMT2A | |
| SCHEMBL26853629 | 0.71 | TBXAS1 (0.33) | PTGS1PTGS2MGLLFAAHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | PTGS1 340/4885PTGS2 308/4885MGLL 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.